Kiora Pharmaceuticals, Inc. (KPRX) NASDAQ
2.44
+0.03(+1.24%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.44
+0.03(+1.24%)
Currency In USD
| Previous Close | 2.41 |
| Open | 2.43 |
| Day High | 2.5 |
| Day Low | 2.41 |
| 52-Week High | 4.18 |
| 52-Week Low | 1.77 |
| Volume | 21,699 |
| Average Volume | 508,043 |
| Market Cap | 10.81M |
| PE | -0.92 |
| EPS | -2.64 |
| Moving Average 50 Days | 2.25 |
| Moving Average 200 Days | 2.33 |
| Change | 0.03 |
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
Newsfile
Feb 19, 2026 1:30 PM GMT
Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026,
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
Newsfile
Jan 27, 2026 12:00 PM GMT
Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to its Scientific Advisory Board. As an advi
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
Newsfile
Dec 01, 2025 11:45 AM GMT
Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on additional and novel formulations of the KIO-100